FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutations are the most frequently identified genetic alterations in AML and are detected in approximately 20–25% of AML patients3,4. This evidence concerns the gene FLT3 and acute myeloid leukemia.